Comparative Pharmacology
Head-to-head clinical analysis: AZACTAM versus AZTREONAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZACTAM versus AZTREONAM.
AZACTAM vs AZTREONAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aztreonam is a monobactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3 in Gram-negative bacteria, leading to cell death. It is active against aerobic Gram-negative bacilli and has no activity against Gram-positive or anaerobic organisms.
Aztreonam is a monobactam antibacterial that inhibits bacterial cell wall synthesis by binding to penicillin-binding protein 3 (PBP3) of Gram-negative bacteria, leading to cell death.
1-2 g intravenously or intramuscularly every 6-8 hours; maximum 8 g/day.
1-2 g IV or IM every 6-8 hours; maximum 8 g/day.
None Documented
None Documented
Clinical Note
moderateAztreonam + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Aztreonam."
Terminal elimination half-life: 1.7-2.2 hours in normal renal function. Prolonged to 6-9 hours in end-stage renal disease; not appreciably removed by hemodialysis.
Terminal elimination half-life is 1.5-2 hours in adults with normal renal function; prolonged to 6-9 hours in end-stage renal disease (CrCl <10 mL/min).
Primarily renal (unchanged drug): 60-75% excreted in urine within 8 hours; 10-15% biliary/fecal. Dosage adjustment required in renal impairment.
Renal: 60-70% unchanged via glomerular filtration and tubular secretion; nonrenal: 30-40% (hepatic metabolism to inactive metabolites and biliary excretion, with <1% fecal elimination).
Category C
Category C
Monobactam Antibiotic
Monobactam Antibiotic